Bivariate analysis Multivariate analysis, n = 793
  Occurrence Cox   Fine-Gray   Cox   Fine-Gray
Characteristics n = 1136 % HR$crude[80% CI] P SHRcrude[80% CI] P HRajusted[95% CI] P* SHRajusted[95% CI] P*
Mode of HIV acquisition       0.0255   0.0373   0.0290   0.0119
Heterosexual 67 12.14 1(Reference)   1(Reference)   1(Reference)   1(Reference)  
Homosexual /Bisexual 57 14.65 1.18 [0.94–1.49]   1.22 [0.97–1.53]   1.45 [0.97–2.16]   1.62 [1.09–2.41]  
Injection drug use  6  7.14 0.51 [0.29–0.88]   0.52 [0.30–0.90]   0.99 [0.38–2.52]   0.77 [0.30–1.94]  
Other/Unknown  6  5.41 0.40 [0.23–0.70]   0.45 [0.26–0.78]   0.30 [0.09–0.97]   0.39 [0.12–1.28]  
Year of first HAART       <0.0001   <0.0001   <0.0001   <0.0001
[2000–2001] 30  9.58 1(Reference)   1(Reference)   1(Reference)   1(Reference)  
[2002– 2003] 32 13.22 1.78 [1.28–2.48]   1.52 [1.10–2.10]   1.44 [0.80–2.59]   1.32 [0.75–2.31]  
[2004– 2005] 60 23.72 4.48 [3.30–6.08]   3.15 [2.38–4.17]   3.02 [1.72–5.29]   2.54 [1.56–4.13]  
[2006– 2008] 14  4.27 1.37 [0.88–2.13]   0.83 [0.55–1.25]   0.90 [0.41–1.96]   0.65 [0.32–1.32]  
First HAART regimen       0.0151   0.1588   0.0548   0.4172
2NRTI + 1PI/1PIb 52 12.81 1(Reference)   1(Reference)   1(Reference)   1(Reference)  
2NRTI + 1NNRTI 35  9.21 0.53 [0.40–0.70]   0.66 [0.50–0.87]   0.56 [0.34–0.91]   0.73 [0.46–1.16]  
Other 49 14.00 0.85 [0.66–1.11]   0.89 [0.69–1.15]   0.89 [0.55–1.44]   0.89 [0.55–1.43]  
VL at Ti (log10 copies/mm3) N= 829 100%   0.0018   0.0046   0.0266   0.0537
[1.7 – 4.0] 20 10.47 1(Reference)   1(Reference)   1(Reference)   1(Reference)  
[4.0–5.0] 35 10.87 1.23 [0.85–1.76]   1.09 [0.76–1.56]   1.18 [0.65–2.13]   1.07 [0.60–1.90]  
≥ 5.0 57 18.04 2.21 [1.58–3.09]   1.95 [1.40–2.71]   1.90 [1.08–3.34]   1.69 [0.98–2.89]  

* P-value obtained by backward stepwise regression
** Ti : Time of HAART initiation
PIb = boosted protease inhibitor
$ Hazard Ratio obtained by Cox model
Subdistribution Hazards Ratio obtained by Fine-Gray model
Table 4: Baseline risk factors of first line HAART discontinuation for treatment simplification: Cox and Fine-Gray models
Goto home»